Given Imaging's M2A to be Reimbursed by Portuguese Hospital System

First European Country to Offer Capsule Endoscopy Reimbursement for Small Bowel Disorders to Entire Population

2/20/2003 - Yoqneam, Israel - Given Imaging Ltd. (NASDAQ: GIVN) announced today that the Portuguese Ministry of Health has initiated reimbursement for capsule endoscopy for the Portuguese public hospital system. Reimbursement will be effective March 1, 2003.

"Capsule endoscopy is an effective tool for diagnosing small bowel disorders in a non-invasive, patient-friendly manner. Reimbursement coverage will allow more hospitals to offer this diagnostic procedure to patients that suffer from disorders of the small bowel," said Dr. Hermano Gouveia, president of the Portuguese Endoscopy Society.

"We are pleased that the Portuguese Ministry of Health has issued reimbursement coverage for public hospitals throughout Portugal. This is a major milestone for Given Imaging and further validates our belief that capsule endoscopy is becoming a first line tool for diagnosing small bowel disease", said Gavriel D. Meron, President and CEO of Given Imaging Ltd.

Portugal has a population of 10.3 million.

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues, and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03